According to a recent report by Future Market Insights, the global therapeutic nuclear medicine market is projected to grow at a compound annual growth rate (CAGR) of 4.10% from 2024 to 2034, with an estimated market valuation of USD 1.32 billion in 2024. By 2034, this figure is expected to rise to USD 1.97 billion, fueled by increasing incidences of cancer, bone deformities, and neurological malignancies, particularly in developing countries. This growth is also supported by advancements in radiopharmaceutical diagnostic technologies.
The market expansion is driven by a robust product pipeline and government initiatives aimed at improving access to nuclear medications, especially in palliative therapy. As treatment options for bone metastasis remain limited, there is a significant demand for innovative therapeutic nuclear medicines. The rising prevalence of chronic diseases presents numerous research opportunities, paving the way for the development of effective solutions in the coming decade.
Despite the promising outlook, market players are expected to approach the upcoming years with caution and flexibility, considering the challenges inherent in the industry. While radioisotopes used in nuclear medicine therapeutics offer new avenues for research and development, concerns regarding radiation safety, contamination, and the short half-lives of radionuclides pose potential hurdles. Nonetheless, advancements in low-penetration radionuclides are anticipated to enhance therapeutic outcomes.
An analyst at Future Market Insights stated, “Over the subsequent decade, market expansion is anticipated to be aided by new research possibilities presented by radioisotopes in nuclear medicine therapies. However, market value is dwindling due to pollution, short half-lives of radionuclides, and safety concerns. It is anticipated that low-penetration radionuclides will enhance therapeutic results. The market is evolving due to the availability of therapeutic nuclear drugs for palliative care and the expansion of research into neurological, cancer, and bone abnormalities.”
As the global therapeutic nuclear medicine market continues to evolve, it is positioned to become a crucial component of modern medical treatment, offering hope to patients with complex health challenges.
Key Takeaways from the Therapeutic Nuclear Medicines Market Report:
- The therapeutic nuclear medicine industry in the United Kingdom is projected to experience a CAGR of 3.5% through 2034.
- Germany’s therapeutic nuclear medicine market is estimated to demonstrate a CAGR of 4.4% by 2034.
- The therapeutic nuclear medicines industry in Russia is anticipated to see a CAGR of 6.4% from 2024 to 2034.
- France’s therapeutic nuclear medicine sector is projected to showcase a CAGR of 5.0% through 2034.
- The Italy therapeutic nuclear medicine market is anticipated to display a CAGR of 5.4% by 2034.
Increased Market Attention: Delve into Detailed Trends and Analysis with Our Report!
Competitive Landscape of the Therapeutic Nuclear Medicine Market:
Key players are focusing on researching novel development of therapeutic nuclear medicines to increase their penetration across the globe, especially in price-sensitive countries. For this, they employ various technologies and invest in research and development, medical trials, and novel radiology practices.
Players are further introducing new nuclear medicines in the market to cure cancer patients and diminish the existence of cancer and cardiovascular diseases. Market participants are offering their products for clinical trials to increase their visibility among potential prospects. Research and development in molecular radiology help players deliver many benefits to their patients, like extensive fitness care, initial drug trials, fast report delivery, and extended medical reach.
Recent Developments in the Therapeutic Nuclear Medicines Market:
- The International Atomic Energy Agency (IAEA) and The University of Texas MD Anderson Cancer Center teamed together in January 2024 to create an IAEA Collaborating Center to advance radiation oncology, radiation physics, radiology, nuclear medicine, and nutrition, emphasizing healthcare globally.
- Advanced Nuclear Medicine services, including FDG PET/CT imaging, were introduced in January 2024 at BARC’s Radiation Medicine Research Centre (RMRC) in Kolkata. The center’s goals are to teach medical and scientific graduates, conduct research and development in nuclear medicine imaging and radiopharmaceutical creation, and offer accessible, cutting-edge diagnostic and therapeutic services to India’s eastern and northeastern regions.
Key Companies in the Therapeutic Nuclear Medicine Market:
- Bayer AG
- GE Healthcare
- Novartis AG
- Cardinal Health Inc.
- Mallinckrodt plc.
- Lantheus Medical Imaging Inc.
- Bracco Imaging S.p.A
- Eckert & Ziegler
- Curium Pharma
- International Isotopes Idaho, Inc.
- Medi-Radiopharma Co., Ltd.
Key Segments:
By Treatment Type:
- Radium-223
- Iodine-131
- Leutitium-177
- Yttrium-90
- Samarium-153
- Strontium-89
- Rhenium-188+Rhenium-186
- Erbium- 169
- Phosphorous-32
- Others
By Indication:
- Prostate Cancer
- Painful Bone Metastases
- Thyroid Cancer
- Neuroblastoma
- Synovitis
- Non-Hodgkin’s Lymphoma
- Hepatic Metastases
- Brain Tumour
- Others
By Distribution Channel:
- Hospitals
- Ambulatory Surgical Centers
- Cancer Research Institutes
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East and Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube